menu search

EDSA / Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Edesa is one of 4 pharmaceutical companies that received a grant from the Canadian government to develop a drug to treat COVID-19. EB01 achieved all endpoints in phase 2 clinical trial in the treatment of patients with allergic contact dermatitis. Read More
Posted: Apr 18 2022, 13:53
Author Name: Seeking Alpha
Views: 102167

EDSA News  

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

By Accesswire
March 16, 2023

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from more_horizontal

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

By Seeking Alpha
April 18, 2022

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa is one of 4 pharmaceutical companies that received a grant from the Canadian government to develop a drug to treat COVID-19. EB01 achieved all e more_horizontal


Search within

Pages Search Results: